Efficacy of Orlistat on Hyperbilirubinemia in Full Term Neonates

Background and Objective: Jaundice is common in infants and occurs because of hyperbilirubinemia, which can lead to brain injury in neonates. Phototherapy, in addition to its serious side effects, does not seem to be enough in resolving jaundice. This clinical trial aims to compare the efficacy of o...

Full description

Saved in:
Bibliographic Details
Main Authors: M Habibi, E Bahadoran, F SamieeRad, A Javadi, G Roozbehani
Format: Article
Language:English
Published: Babol University of Medical Sciences 2024-03-01
Series:Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul
Subjects:
Online Access:http://jbums.org/article-1-11459-en.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850104180700610560
author M Habibi
E Bahadoran
F SamieeRad
A Javadi
G Roozbehani
author_facet M Habibi
E Bahadoran
F SamieeRad
A Javadi
G Roozbehani
author_sort M Habibi
collection DOAJ
description Background and Objective: Jaundice is common in infants and occurs because of hyperbilirubinemia, which can lead to brain injury in neonates. Phototherapy, in addition to its serious side effects, does not seem to be enough in resolving jaundice. This clinical trial aims to compare the efficacy of orlistat and phototherapy combination therapy with that of phototherapy alone in the treatment of neonatal jaundice. Methods: This clinical trial was performed on 120 term neonates with jaundice. Block randomization was used to allocate the infants to the intervention and control groups. The intervention group received orlistat (4 mg/kg body weight) for three consecutive oral doses at the first, second and third day of hospitalization, along with phototherapy. The control group received a placebo and phototherapy. Total and direct plasma bilirubin levels were measured at baseline (before intervention) as well as 24 and 72 h after treatment. Findings: There were no statistically significant differences between the two groups in terms of infant sex, weight, or age. The mean total and direct bilirubin levels in the experimental group did not change compared to those in the control group at the end of the trial (10.44±1.35 vs. 10.6±2.8 and 0.4±0.1 vs. 0.5±0.1, respectively). Conclusion: Orlistat appears to be ineffective in accelerating bilirubin reduction in neonates with jaundice, at least for the first three days of life.
format Article
id doaj-art-ff62bceb8aef44eda441b9cd7835ed48
institution DOAJ
issn 1561-4107
2251-7170
language English
publishDate 2024-03-01
publisher Babol University of Medical Sciences
record_format Article
series Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul
spelling doaj-art-ff62bceb8aef44eda441b9cd7835ed482025-08-20T02:39:23ZengBabol University of Medical SciencesMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul1561-41072251-71702024-03-012600Efficacy of Orlistat on Hyperbilirubinemia in Full Term NeonatesM Habibi0E Bahadoran1F SamieeRad2A Javadi3G Roozbehani4 1.Department of Pediatrics, School of Medicine, Qazvin University of Medical Sciences, Qazvin, I.R.Iran. 2.Student Research Committee, Qazvin University of Medical Sciences, Qazvin, I.R.Iran. 3.Department of Pathobiology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, I.R.Iran. 4.Department of Community Medicine, School of Medicine, Qazvin University of Medical Sciences, Qazvin, I.R.Iran. 1.Department of Pediatrics, School of Medicine, Qazvin University of Medical Sciences, Qazvin, I.R.Iran. Background and Objective: Jaundice is common in infants and occurs because of hyperbilirubinemia, which can lead to brain injury in neonates. Phototherapy, in addition to its serious side effects, does not seem to be enough in resolving jaundice. This clinical trial aims to compare the efficacy of orlistat and phototherapy combination therapy with that of phototherapy alone in the treatment of neonatal jaundice. Methods: This clinical trial was performed on 120 term neonates with jaundice. Block randomization was used to allocate the infants to the intervention and control groups. The intervention group received orlistat (4 mg/kg body weight) for three consecutive oral doses at the first, second and third day of hospitalization, along with phototherapy. The control group received a placebo and phototherapy. Total and direct plasma bilirubin levels were measured at baseline (before intervention) as well as 24 and 72 h after treatment. Findings: There were no statistically significant differences between the two groups in terms of infant sex, weight, or age. The mean total and direct bilirubin levels in the experimental group did not change compared to those in the control group at the end of the trial (10.44±1.35 vs. 10.6±2.8 and 0.4±0.1 vs. 0.5±0.1, respectively). Conclusion: Orlistat appears to be ineffective in accelerating bilirubin reduction in neonates with jaundice, at least for the first three days of life.http://jbums.org/article-1-11459-en.pdfhyperbilirubinemiaphototherapyneonatesorlistat.
spellingShingle M Habibi
E Bahadoran
F SamieeRad
A Javadi
G Roozbehani
Efficacy of Orlistat on Hyperbilirubinemia in Full Term Neonates
Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul
hyperbilirubinemia
phototherapy
neonates
orlistat.
title Efficacy of Orlistat on Hyperbilirubinemia in Full Term Neonates
title_full Efficacy of Orlistat on Hyperbilirubinemia in Full Term Neonates
title_fullStr Efficacy of Orlistat on Hyperbilirubinemia in Full Term Neonates
title_full_unstemmed Efficacy of Orlistat on Hyperbilirubinemia in Full Term Neonates
title_short Efficacy of Orlistat on Hyperbilirubinemia in Full Term Neonates
title_sort efficacy of orlistat on hyperbilirubinemia in full term neonates
topic hyperbilirubinemia
phototherapy
neonates
orlistat.
url http://jbums.org/article-1-11459-en.pdf
work_keys_str_mv AT mhabibi efficacyoforlistatonhyperbilirubinemiainfulltermneonates
AT ebahadoran efficacyoforlistatonhyperbilirubinemiainfulltermneonates
AT fsamieerad efficacyoforlistatonhyperbilirubinemiainfulltermneonates
AT ajavadi efficacyoforlistatonhyperbilirubinemiainfulltermneonates
AT groozbehani efficacyoforlistatonhyperbilirubinemiainfulltermneonates